Description

BSE has sought clarification from Sun Pharmaceutical Industries Ltd and India Tourism Development Corporation Ltd regarding news articles. Sun Pharma has submitted its reply while ITDC's response is awaited.

Summary

BSE’s Surveillance department (DOSS) has sought clarifications from two listed companies — Sun Pharmaceutical Industries Ltd and India Tourism Development Corporation Ltd — regarding news articles circulating in newspapers, websites, and television channels. This is a routine exercise to verify accuracy of news and keep members and investors informed.

Key Points

  • BSE Notice No. 20260410-42 dated 10 April 2026 pertains to clarification requests on news articles.
  • Sun Pharmaceutical Industries Ltd (Scrip Code: 524715) has submitted its reply in response to a news article from moneycontrol.com; the reply is attached to the notice.
  • India Tourism Development Corporation Ltd (Scrip Code: 532189) has been asked to clarify a news article from ndtvprofit.com; reply is still awaited.
  • Notice issued by Sanjay Jain (Deputy Vice President, Surveillance) and Shreya Ghose (Manager, Surveillance).

Regulatory Changes

No regulatory changes are introduced by this circular.

Compliance Requirements

  • India Tourism Development Corporation Ltd (Scrip Code: 532189) is required to submit its clarification to BSE regarding the news article published on ndtvprofit.com.
  • No compliance action is required from other market participants.

Important Dates

  • Notice Date: 10 April 2026
  • Sun Pharma reply: Received and attached as of notice date.
  • ITDC reply: Awaited as of notice date.

Impact Assessment

This is a routine surveillance disclosure with minimal market impact. Sun Pharma’s clarification may provide informational value to investors monitoring the stock. ITDC’s pending response could attract attention until the clarification is submitted. No trading restrictions or penalties are imposed.

Impact Justification

Routine surveillance notice seeking clarifications on news articles. Sun Pharma has already responded; ITDC reply pending. No regulatory changes or compliance mandates involved.